🔹 Adjusted EPS: $3.84 (Est. $3.84) 🟡
🔹 Operating Revenue: $44.99B (Est. $44.84B) 🟢
🔹 Medical Membership: 45.7M (Est. 46.22M) 🔴
FY25 Guidance:
🔹 Adj EPS: $34.15-$34.85 (Est. $34.87) 🔴
Q4 Segments:
Health Benefits:
🔹 Operating Revenue: $37.6B (UP +3% YoY)
🔹 Adjusted Operating Gain: $0.3B (DOWN from $0.8B YoY)
Carelon (CarelonRx & Carelon Services):
🔹 Operating Revenue: $14.7B (UP +19% YoY)
🔹 Adjusted Operating Gain: $0.8B (UP +32% YoY)
Operational Metrics:
🔹 Benefit Expense Ratio: 92.4% (UP 320 bps YoY)
🔹 Adjusted Operating Margin: 2.3% (DOWN from 3.2% YoY)
🔹 Days in Claims Payable: 42.9 days (DOWN from 47.3 YoY)
Shareholder Returns:
🔹 Quarterly Dividend: Increased by 5% to $1.71/share
🔹 Share Buyback: $1.8B in Q4 2024
Strategic Commentary:
🔸 CEO emphasized efforts to simplify the healthcare experience, improve Carelon’s impact, and leverage innovative care models for sustainable growth.
🔸 Investments in cost management and efficiency continue to drive profitability, despite headwinds from Medicaid cost trends.